UCSD’s Elaine Muchmore receives ASH Exemplary Service Award

Yescarta demonstrates improved outcomes for r/r LBCL

Kite announced findings from three new analyses for Yescarta (axicabtagene ciloleucel) that demonstrate improved outcomes for people living with relapsed or refractory large B-cell lymphoma, which were presented at 66th American Society of Hematology annual meeting.

December 13, 2024

Vol.50 No.46

Clinical Roundup

Calquence + Venetoclax shows superior PFS in untreated CLL in AMPLIFY phase III trial

Positive results from the AMPLIFY phase III trial showed AstraZeneca’s Calquence (acalabrutinib) in combination with venetoclax demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard-of-care chemoimmunotherapy in previously untreated adult patients with chronic lymphocytic leukemia.

December 13, 2024

Vol.50 No.46

In Brief

ASH recognizes 10 hematologists with 2024 honorific awards

The American Society of Hematology will recognize exemplary hematologists who have made significant contributions to the field with several honorific awards at the 2024 ASH Annual Meeting and Exposition in San Diego on December 7-10.

June 21, 2024

Vol.50 No.25

In Brief

Murphy, McKay, Nodora, Ballantyne, Stupack named associate directors at UCSD Moores

Diane Simeone, director of Moores Cancer Center at UC San Diego Health, has expanded her leadership team.

June 14, 2024

Vol.50 No.24

Clinical Roundup

Alligator Bioscience initiates phase I study of intratumoral mitazalimab in locally advanced pancreatic cancer

Alligator Bioscience has announced the initiation of a phase I clinical study (NCT06205849) to evaluate the safety and efficacy of mitazalimab (CD40 mAb agonist) injected intratumorally at the time of surgical irreversible electroporation (IRE) in patients with locally advanced pancreatic cancer.

May 17, 2024

Vol.50 No.20